![]() The contents of this website are for informational purposes only and do not constitute medical is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Join CreakyJoints’ patient-centered research registry and participate in voluntary studies about managing arthritis. Be Part of Rheumatoid Arthritis Research with ArthritisPower Instead, they theorized that people taking biologics - despite generally have more severe disease than those who only use conventional DMARDs - were probably benefitting from the “overall decrease in inflammation” that biologics provide. All of these medications work differently from each other, but they act on specific immune system pathways to reduce inflammation.īecause patients in this study fared equally well regardless of which class of biologic drug they were taking, the authors suggested that a specific mechanism of action (such as targeting TNF or IL-6) is unlikely to be responsible for reducing dementia risk. There are also other kinds of targeted therapies called JAK inhibitors. There are many different classes of biologics that are approved to treat RA, including TNF inhibitors, IL-1 blockers, IL-6 blockers, IL-17 blockers, B-cell inhibitors, and T-cell inhibitors. Patients on any biologic drug were 17 percent less likely than those using only a traditional DMARD to have developed dementia. The researchers determined that the incidence of dementia was significantly higher among RA patients who were being treated with a conventional DMARD (disease modifying anti-rheumatic drug), such as methotrexate, than it was among those who were on a biologic drug like infliximab (Remicade) or etanercept (Enbrel). The researchers identified more than 140,000 RA patients who were enrolled in Medicare for at least one year and had no history of dementia when the study began.ĭuring the study period, nearly 3,800 of these RA patients developed dementia. The study, which was led by Sebastian Sattui, MD, a rheumatologist at Hospital for Special Surgery in New York City, relied on Medicare claims data that was submitted between 2006-2017. ![]() Research presented at ACR Convergence 2020, the American College of Rheumatology’s annual (virtual) meeting, suggests that it may be possible.Īlthough this study does not directly prove that biologic drugs prevent dementia, the researchers found compelling evidence that biologic drugs might reduce an RA patient’s risk of age-related memory issues. So, can treating RA with biologic drugs that block inflammatory proteins mitigate this risk? Meanwhile, people with rheumatoid arthritis (RA) - an inflammatory autoimmune condition - are more apt than others to develop dementia as they get older. In recent years a number of studies have identified a connection between inflammation and various types of dementia, including Alzheimer’s disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |